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Objective: There is great need of biomarkers for research and clinical purposes in COPD. This
study explored the relationships between ten putative plasma biomarkers of COPD and phys-
iological measures of reduced lung function.
Methods: FEV1, FVC, residual volume/total lung capacity (RV/TLC) and CO diffusion capacity
(DLCO) were assessed in 357 subjects from the Swedish Twin Registry. The lung function
measures were studied in relation to plasma levels of desmosines, C-reactive protein (CRP),
plasminogen inhibitor activator (PAI-1) concentration and activity, tissue inhibitor of metallo-
proteinase (TIMP-1), clara cell protein 16 (CC16), surfactant protein D (SPD), matrix metallo-
proteinase 9 (MMP-9), hepatocyte growth factor (HGF) and interleukin (IL)-8.
Results: After adjustments for age, sex, height, BMI and smoking, FEV1 was significantly asso-
ciated with PAI-1 activity and desmosines. RV/TLC was significantly associated with CC16, PAI-
1 concentration and PAI-1 activity, and DLCO was significantly associated with desmosines,
TIMP-1 and CRP. When the multivariate analysis was restricted to subjects with COPD (i.e.,
FEV1/FVC < 0.70), CRP and desmosines were inversely associated with lung function.R&D, 43183 Mo¨lndal, Sweden. Tel.: þ46 31 3566094.
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e Verdier), Ulf.Nihlen@astrazeneca.com (U. Nihle´n), martin.anderson@sodersjukhuset.se (M.
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Blood biomarkers and lung function 1251Conclusion: Several biomarkers were associated with lung function in this cross-sectional
study. Especially CRP and desmosines could be useful markers to assess disease severity in
subjects with COPD.
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Lung function in adults, as measured by spirometry, is char-
acterized by slow and irreversible age-related decline. The
rate of decline is accelerated in some individuals, e.g., due to
smoking, environmental exposures or individual suscepti-
bility. Chronic obstructive pulmonary disease (COPD)
develops slowly and is usually the result of many years of
progressive lung function decline. Today, there are few
possibilities to monitor this process, besides repeated exam-
inations of lungphysiology. There is great need for biomarkers
that could be used as sensitive measures of the disease
activity and assist as predictors of lung function decline.1
Many blood biomarkers have been proposed in COPD,
and the markers are assumed to measure different parts of
the disease process. C-reactive protein (CRP), fibrinogen,
interleukin (IL)-6, IL-8, i.e., unspecific markers of systemic
inflammation, have been related to COPD and/or reduced
FEV1.
2e7 These markers could hypothetically reflect the
inflammatory activity in the lungs, and thereby disease
progression. Plasma levels of clara cell protein 16 (CC16)
and surfactant protein D (SPD) have been considered as
more lung specific markers, since these proteins are
secreted from cells in the bronchial epithelium.8,9 Desmo-
sines, matrix metalloproteinase 9 (MMP-9) and tissue
inhibitor of metalloproteinase (TIMP-1) are assumed to be
associated with the degradation of lung tissue.5,7 Desmo-
sines are linked to the elastic fibers and released to the
circulation as a result of elastin degradation. We recently
reported that desmosines in plasma and urine were asso-
ciated with several physiological measures of lung func-
tion.10 Hepatocyte growth factor (HGF) has been suggested
as a factor related to tissue repair in pulmonary
diseases.11,12 Plasminogen activator inhibitor 1 (PAI-1) is an
inhibitor of fibrinolysis and serves as a pro-thrombotic
factor. PAI-1 is associated with inflammation and features
of the metabolic syndrome.13 It was recently reported that
COPD is associated with increased PAI-1 concentrations in
plasma and sputum.14
The purpose of the present study was to explore ten
plasma biomarkers, previously associated with COPD or
reduced lung function, by studying the relationships
between the biomarkers and different physiological
measures of lung function in a population-based sample of
Swedish twins.Methods
Study population
The study was based on the Swedish Twin Registry (STR),
which contains information on more than 80,000 twin pairs(n Z 160,000) born from 1886 to 2000. Between 1998 and
2002, all living twins in the STR born in 1958 or earlier
were contacted using a computer-assisted telephone
interview developed for the SALT (Screening Across the
Lifespan Twin) study.15 The interview included a checklist
of common diseases and respiratory symptoms, as well as
smoking habits. From the population of 26,516 twin pairs
(n Z 53,032) where both participated in the telephone
interview, 1030 twins in 515 pairs were selected to
participate in more in-depth measurements of lung func-
tion. To assure that the sample would contain twins with
symptoms of respiratory disease (self-reported symptoms
of cough, chronic bronchitis, emphysema or asthma)
disease concordant and discordant twins were prioritized
over symptom free twin pairs. The selection of subjects
and lung function testing procedures has been described
previously.16 In total, 392 twins (38%) of 1030 twins
accepted the invitation to participate. Of them, accept-
able measurements of forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC), residual volume/total
lung capacity (RV/TLC) and carbon monoxide diffusing
capacity (DLCO), were obtained for 357 individuals. Based
on the answers from the telephone interview and subse-
quent questionnaire at the clinic, smoking status was
defined as current smoker, ex-smoker, never-smoker or
occasional (social) smoker. The number with information
about plasma biomarkers ranged from 246 (for HGF) to 347
(for CRP). Of the 357 study subjects, there were 87 pairs
of monozygotic twins, 39 dizygotic pairs of same-sex, 37
twin pairs of opposite sex and 31 unmatched twins. The
study was approved by the Ethics Committee at Karolinska
Institutet, No.03-461. All subjects signed informed
consent.Determination of blood biomarkers
Plasma was prepared from blood, collected in 10-mL
Vacutainer tubes with EDTA, by centrifugation at 500 g
for 10 min at room temperature. For the preparation of
serum, blood was collected in 10-mL Vacutainer tubes and
allowed to stand at room temperature for 1 h. It was then
centrifuged at 500 g for 10 min at room temperature.
The desmosine data have been reported previously but
are included here for comparison.10 The concentration of
the sum of total (free plus peptide bound) desmosine and
isodesmosine in plasma (desmosines) was measured by
liquid chromatography combined with tandem mass spec-
trometry.10 The lower and upper limits of quantification
were 0.1 and 2.0 nmol/L, respectively, with coefficients of
variation of 5e6% at the low end and 8e9% at the high end.
C-reactive protein was measured with a high-sensitive
assay (hsCRP) using near infrared particle immunoassay
1252 G. Engstro¨m et al.(Turbidimetry NIPIA) with a detection range of 0.2e380
mg/L.
Human clara cell protein (CC16) (range 2e100 ng/mL)
and human surfactant protein D (SPD) (range 1.56e100 ng/
mL) were measured in plasma using ELISA immunoassays
from BioVendor Laboratorni medicina, a.s., Modrice, Czech
Republic.
Human hepatocyte growth factor (HGF) (range
10e10,000 pg/mL), interleukin-8 (IL-8) (range
2.4e2500 pg/mL), and tissue inhibitor of metalloproteinase
1 (TIMP-1) (range 55e40,000 pg/mL) were measured in
plasma using an MSD 96-well multi-array system from Meso
Scale Diagnostics (Gaithersburg, Maryland, USA). Matrix
metalloproteinase 9 (MMP-9) was measured in serum in the
range 0.12e500 ng/mL using the same system from Meso
Scale Diagnostics.
The plasma concentration of plasminogen activator
inhibitor type 1 (PAI-1) was measured by a Quantikine ELISA
immunoassay from R&D Systems (Minneapolis, MN, USA) in
the range 0.31e20 ng/mL. The PAI-1 activity in plasma was
measured by a functional assay ELISA kit (range
3.12e220 U/mL) from Molecular Innovations, Novi, Michi-
gan, USA.
Some individuals had plasma biomarker concentrations
below the lowest level of quantification (LLOQ). If the
number below LLOQ was low, a value corresponding to 50%
of the LLOQ was assigned. This procedure was used for
CC16 in 24 cases, for TIMP-1 in 3 cases and for SPD in one
case. For PAI-1 activity 137 cases (45%) were below LLOQ
and these were grouped in a separate category (see
statistics section).Statistical methods
The median and range for levels of biomarkers were
calculated and presented for descriptive purposes. Multiple
linear regression was used to explore whether the following
factors were associated with biomarker concentrations:
age, gender, height, smoking status and BMI. Gender and
smoking (current and occasional smokers vs. never smokers
and former smokers) were modeled as dichotomous vari-
ables, age, height and BMI were modeled as continuous
variables, and levels of the biomarkers were fitted as
dependent variables.
Multiple linear regression was also used to assess the
relationship between biomarkers and lung function
measures, with lung function measures as the dependent
variables. A separate analysis of the relationship between
biomarkers and lung function was conducted for those with
and without COPD. In both analyses, the data were
adjusted for confounding factors, i.e. age, gender, height,
smoking and BMI.
Due to positively skewed distributions, log-transformed
(natural logarithm) values of desmosines, CRP, MMP-9, SPD,
IL-8, PAI-1 concentration and HGF were used in all multiple
regression analyses. CC16 and TIMP-1 were not log trans-
formed, since the distributions were close to normal. The
relationships between lung function measures and
biomarkers are presented as standardized beta-
coefficients.The lung function values were also studied in relation to
quartiles of the biomarker concentrations. The study pop-
ulation was divided into quartiles according to the
concentrations of each biomarker, with equal numbers of
men and women in each quartile. The mean lung function
values were compared across the quartiles, after adjust-
ment for confounding factors in a general linear model.
Since a high proportion of the subjects (137/304) had
PAI-1 activity below the lowest level of quantification
(LLOQ), we did not use linear regression to study the PAI-
activity. Instead, PAI-1 activity was categorized. Subjects
with PAI-1 activity below LLOQ formed a reference category
and those with PAI-1 activity above LLOQ were divided into
quartiles. The relationships between categories of PAI-1
activity and lung function measures were assessed for
significance in a general linear model. P-values were
computed for the overall relationship with PAI-1 activity
and for the difference between the highest and lowest
category.
The relationship between concentrations of biomarkers
and lung function was also studied within twin pairs of the
same gender. The biomarker and lung function values of the
first twin were subtracted from the corresponding values in
the second twin. Relationships between the differences
were assessed using Spearman rank correlations.
Results
Study cohort
A total of 357 individuals (131 men, 226 women) had
complete information on lung function and at least one of
the blood biomarkers. Mean age was 59.1  8.5 years. Age,
gender, and COPD status of the participants in relation to
smoking are presented in Table 1. The number of subjects
with information about the various biomarkers ranged
between 246 and 347 (Table 1).
Factors associated with concentrations of
biomarkers
Multiple linear regressions were performed, with the
biomarker as dependent variable, and age, sex, height, BMI
and smoking as independent variables (Table 2). Except for
MMP-9 and PAI-1, all biomarkers were positively associated
with age. Desmosines and IL-8 were significantly higher in
women compared to men. Current smokers had significantly
higher levels of CRP, PAI-1, TIMP-1 and HGF, and signifi-
cantly lower CC16, after adjustments for age, sex, BMI and
height.
Relationships between biomarkers and lung
function measures
The relationships between biomarkers and measures of lung
function are presented in Table 3. After adjustments for
age, sex, height, smoking and BMI, desmosines were
significantly and inversely associated with FEV1 and DLCO.
CC16 was significantly associated with RV/TLC (inversely).
CRP was inversely associated with FVC and DLCO. PAI-1
Table 1 Lung function, smoking status and levels of
biomarkers in the study cohort.
N 357








FEV1 (L) (men) 3.2  0.72
FEV1 (L) (women) 2.4  0.52
FVC (L) (men) 4.6  0.80
FVC (L) (women) 3.3  0.62
DLCO (mL/min/mmHg) (men) 28  6.3
DLCO (mL/min/mmHg) (women) 20  4.7
RV/TLC (men) 0.37  0.08







Desmosines, nmol/L (n Z 326) 0.47 (0.16e1.4)
SPD, ng/mL (n Z 298) 66 (8.6e280)
MMP-9, ng/mL (n Z 279) 55 (15e330)
IL-8, pg/mL (n Z 303) 4.9 (0.82e70)
HGF, pg/mL (n Z 246) 120 (57e320)
PAI-1 concentration, ng/mL (n Z 323) 2.4 (0.31e15)
CRP, mg/L (n Z 347) 1.6 (0e39)
CC16, ng/mL (n Z 293) 4.6 (1.0e15)
TIMP-1, pg/mL (n Z 299) 150 (2.1e320)
PAI-1 activity, U/ml (n Z 304) 3.5 (1.6e80)
Values are median (range), mean  standard deviation or %.
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(positively), and TIMP-1 was negatively associated to DLCO.
The study sample was also divided into quartiles based
on the biomarker concentrations, and the lung functionTable 2 Factors associated with plasma concentrations of nine
Desmosinesa SPDa MMP-9a IL-8a
N 326 298 279 303
Age (1 yr) 0.023*** 0.012 *** 0.0010 0.014***
Female
(vs male)
0.090* 0.026 0.13 0.22*
Smoking
(Yes vs No)
0.055(*) 0.016 0.010 0.13(*)
BMI (1 kg/m2) 0.018*** 0.013(*) 0.022** 0.014(*)
Height (1 cm) 0.0017 0.001 0.0077 0.0051
(*) p < 0.1 *p < 0.05 **p < 0.01 ***p < 0.001.
Values are beta-coefficients from a multiple linear regression.
a Log transformed values were used in the analysis.measures were compared across the quartiles in a general
linear model (Supplement Table 1). The results from this
analysis were consistent with the findings from the multiple
linear regression models.Biomarkers and lung function in subjects with COPD
The relationships between biomarkers and lung function
were also analyzed in subjects with COPD, defined as
FEV1/FVC < 0.70. The numbers with COPD ranged
between 90 and 110 for the various biomarkers (Table 4).
Desmosines were significantly and inversely associated
with FEV1, FVC and DLCO after adjustments for con-
founding factors. Desmosines showed no significant rela-
tionship with lung function in subjects without COPD,
except for a significant relationship between desmosines
and DLCO (b Z 0.12, p Z 0.026) (data not shown). In
subjects with COPD, CRP was inversely associated with
FEV1, FVC, RV/TLC and DLCO (Table 4). CRP was not
significantly associated with lung function in subjects
without COPD (data not shown).
MMP-9 was associated with RV/TLC in subjects with
COPD (bZ 0.20, p < 0.05). No other significant relationship
was observed in the subgroup with COPD.PAI-1 activity
Since a substantial number of subjects had PAI-1 activity
below LLOQ, PAI-1 activity was categorized into five
groups (Table 5). High PAI-1 activity was associated with
BMI, but not significantly with age, sex or smoking. After
adjustments for age, sex, BMI, smoking and height, FEV1
and FVC were significantly lower, and RV/TLC was signifi-
cantly higher, in subjects with high PAI-1 activity.
There was no significant relationship between PAI-1
activity and lung function when subjects with COPD
(n Z 98) were analyzed separately. However, when
comparing the highest vs. lowest categories of PAI-1
activity in subjects without COPD, FEV1 and FVC were
significantly lower and RV/TLC significantly higher after
adjustments for confounding factors (not shown).biomarkers. Results from multiple linear regression analyses.
HGFa CC16 TIMP1 PAI-1
concentrationsa
CRPa
246 293 299 323 347
0.013*** 0.091*** 1.4*** 0.0046 0.028***
0.046 0.10 9.2 0.075 0.15
0.082* 1.15*** 11* 0.19* 0.35**
0.012** 0.0052 2.2*** 0.056*** 0.13***
0.0025 0.016 1.1** 0.0087 0.0013
Table 3 Relationships between concentrations of plasma biomarker and measures of lung function. Results from multiple
linear regression analyses.
Desmosinea SPDa MMP-9a IL-8a HGFa CC16 TIMP1 PAI-1
concentrationa
CRPa
N 326 298 279 303 246 293 299 323 347
FEV1 0.10* 0.051 0.046 0.038 0.042 0.068(*) 0.040 0.051 0.069(*)
FVC 0.072(*) 0.030 0.019 0.024 0.021 0.018 0.040 0.031 0.071*
RV/TLC 0.098 0.033 0.061 0.046 0.029 0.14* 0.061 0.10* 0.013
DLCO 0.21*** 0.001 0.001 0.035 0.087(*) 0.019 0.099* 0.026 0.11**
Values are standardized beta-coefficients, adjusted for age, gender, height, BMI and smoking.
(*) p < 0.1 *p < 0.05 **p < 0.01 ***p < 0.001.
a Log transformed values were used in the analysis.
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Correlations of the differences within twin pair of same
gender are presented in Supplementary Table 2. Overall,
there were few significant correlations when intra pair
differences were studied. However, DSPD showed signifi-
cant correlations with DDLCO (r Z 0.35, p < 0.001) and
DFVC (r Z 0.23, p Z 0.03). These correlations remained
significant when the analysis was restricted to 70 pairs with
concordant smoking status. Significant correlations were
also observed between DCC16 and DFEV1, and between
DIL8 and DDLCO.Discussion
The present study investigated the relationships between
a panel of blood biomarkers and physiological measures of
lung function in a population-based sample of twins. CRP,
desmosines, TIMP-1, CC16, PAI-1 activity and PAI-1
concentration were all associated with at least one physi-
ological measure of lung function. However, when subjects
with COPD were analyzed separately, two biomarkers, i.e.,
CRP and desmosines, showed substantial correlations with
several measures of lung function. Except for a significant
association between MMP-9 and RV/TLC, no relationship
was found for any of the other biomarkers in subjects with
COPD.
Several previous studies have explored the relationships
between different biomarkers and reduced lung function orTable 4 Relationships between concentrations of plasma biom
(FEV1/FVC < 0.70). Results from multiple linear regression analy
Desmosinesa SPDa MMP-9a IL-8a
N (Men/women) 46/64 44/58 39/54 44/59
FEV1 0.22* 0.089 0.087 0.010
FVC 0.19* 0.080 0.064 0.024
RV/TLC 0.18 0.090 0.20* 0.021
DLCO 0.30*** 0.036 0.033 0.019
Values are standardized beta-coefficients, adjusted for age, gender,
(*) p < 0.1 *p < 0.05 **p < 0.01 ***p < 0.001.
a Log transformed values were used in the analysis.COPD, and the results have varied a lot between studies. In
a recent report from the Evaluation of COPD Longitudinally
to Identify Predictive Surrogate Endpoints (ECLIPSE)
study,17 FEV1 at baseline was inversely associated with
fibrinogen and CRP, and positively associated with CC16 and
IL-8. CC16 was also associated with change in FEV1 during
follow-up. SPD showed no significant association with
FEV1.
17 In a proteomics study, a large number of
biomarkers, including MMP-9, TIMP-1 and IL-8, were
significantly increased in COPD patients compared to
controls.18 In contrast, lower TIMP-1 and higher IL-8 in
COPD patients were reported by Shaker et al.7 Increased
CRP and IL-8 concentrations were associated with COPD
status in a case-control study of COPD patients and
‘reference subjects’, but no significant association was
found for IL-6 or fibrinogen.6 In a study of COPD patients,
CRP and MMP-9 were associated with rapid FEV1 decline,
but no significant relationship was observed for IL-8, TIMP-
1, IL-6 or fibrinogen.5 It is conceivable that inconsistent
findings in part could be due to differences between study
populations, study designs and degree of control for con-
founding factors. Many biomarkers are strongly correlated
to confounding factors, such as age, sex, smoking and BMI
(Table 2), which illustrates the importance of adequate
control for these factors in studies of COPD and lung
function.
Desmosines and CRP were associated with lung function
in the subgroup with COPD, while no relationships were
found in the group without COPD. In contrast, PAI-1 activity
was associated with lung function in the whole sample andarker and measures of lung function in subjects with COPD
ses.
HGFa CC16 TIMP1 PAI-1
concentrationa
CRPa
40/50 42/53 41/58 45/64 46/64
0.0071 0.047 0.0004 0.019 0.26**
0.0015 0.029 0.016 0.017 0.27***
0.074 0.16 0.039 0.091 0.28**
0.16 0.023 0.102 0.053 0.23**
height, BMI and smoking.
Table 5 Relationships between PAI-1 activity and measures of lung function.
PAI-1 activity p between
groups
(4 df)
<3.1 U/ml 3.1e4.3 U/ml 4.4e6.0 U/ml 6.0e11 U/ml 11e80 U/ml
N 137 41 42 42 42
Men (%) 29 51 38 45 40 0.077
Age, years
(mean  SD)
59  9.0 57  8.0 60  8.6 59  7.2 60  7.8 0.66
BMI, kg/m2
(mean  SD)
24  3.0 25  4.0 26  3.1 26  3.9 28  4.2 <0.001
Smoking (yes) % 25 27 17 31 35 0.35
Lung function
FEV1 (L) 2.8 þ 0.04 2.7 þ 0.07 2.8 þ 0.07 2.9 þ 0.07 2.6 þ 0.07 (p Z 0.003) 0.007
FVC (L) 3.9 þ 0.05 3.8 þ 0.08 3.8 þ 0.08 4.0 þ 0.08 3.6 þ 0.08 (p Z 0.01) 0.024
RV/TLC 0.37 þ 0.005 0.38 þ 0.009 0.38 þ 0.009 0.36 þ 0.009 0.40 þ 0.10 (p Z 0.009) 0.023
DLCO
(mL/min/mmHg)
23 þ 0.38 22 þ 0.68 24 þ 0.67 23 þ 0.67 22 þ 0.69 0.15
Lung function measures are presented as mean values þ standard error adjusted for age, sex, height, BMI and smoking in a general linear
model.
p-values in brackets are compared to reference category <3.1 U/ml.
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found in the COPD group. CRP, desmosines and PAI-1
activity are assumed to reflect different aspects of the
underlying disease process. It could be speculated that CRP
and desmosines could reflect disease activity in established
COPD, while other biomarkers may indicate disease
processes at an early stage or other phenotypes with
reduced lung function.
Of the biomarkers in this study, CRP has been studied
most frequently and was often associated with COPD.2,4
CRP is generally considered a non-specific marker of
systemic inflammation, but it has also been proposed that
CRP could be causally related to the disease process in
COPD.19 However, two large studies of COPD or lung func-
tion using the ‘Mendelian randomization’ approach suggest
that increased CRP concentrations per se have no causal
role.20,21 It therefore seems likely that CRP is an unspecific
risk marker and not a causal risk factor. The relationships
between CRP and lung function could be explained by
reverse causation or ‘systemic spill over’ from lungs to
systemic circulation. Unmeasured confounding factors,
which may include other molecules in the inflammatory
cascade, is another possible explanation for the relation-
ship between CRP and lung function. Similar studies of the
MMP-9 gene have shown inconsistent results with respect to
polymorphisms in the MMP-9 gene and COPD.22,23
There are few previous studies of plasma desmosines in
relation to lung function.10,24,25 It was reported that des-
mosines were higher in COPD patients than in healthy
subjects,24,25 and we recently reported that desmosines in
plasma as well as urine are associated with lung function
measures.10 Desmosines are cross-linking structures of the
elastin fibers, which are released as a result of elastin
degradation. Matrix degradation is an important feature in
COPD and emphysema and biomarkers that reflect this
process could be important for early detection and moni-
toring of disease activity. Even though much elastin islocated in the lungs, it is important to note that desmosines
cannot be considered lung-specific markers, since desmo-
sines also originate from elastin in, e.g., skin and large
blood vessels.
Besides its role as an inhibitor of fibrinolysis, PAI-1 has
also been associated with obesity, metabolic syndrome,
atherosclerosis and inflammation.13 Increased PAI-1
concentrations were reported in plasma and sputum from
COPD patients compared to controls.14 A recent experi-
mental study reported that PAI-1 stimulates inflammation
and migration of inflammatory cells in a culture of alveolar
epithelial cells.26 In the present study, PAI-1 activity
showed substantial correlations with lung function in
subjects without COPD, but not in those with FEV1/
FVC < 0.70. This suggests that PAI-1 activity could reflect
early signs of declining lung function. Even though we
adjusted for BMI, it should be noted that we were unable to
control for all components of the metabolic syndrome. For
example, diabetes and insulin resistance are factors asso-
ciated with low lung function as well as high PAI-1
values.13,27,28
It is well known that concentrations of biomarkers could
differ between studies because of differences between
laboratory methods. In this study, the mean PAI-1 activity
was low and many individuals had values below LLOQ.
Therefore, PAI-1 activity was categorized in the analysis.
However, the Spearman correlation between PAI-1 activity
and PAI-1 concentration was r Z 0.79 and, as expected,
PAI-1 activity was strongly associated with BMI. Therefore,
we have no reason to question the validity of the PAI-1
activity, despite the low mean values in this study.
In contrast to the results for the entire cohort of twins,
the within-pair analysis showed no significant correlation
between lung function and desmosines or CRP, respectively
(Supplement Table 2). These correlations were based on
approximately 100 twin pairs of same gender and the
statistical power was therefore substantially lower. There
1256 G. Engstro¨m et al.were, however, significant correlations between within pair
differences in SPD and lung function measures, which was
in contrast to the results for the entire cohort. Over-
matching is a concern when comparing differences within
twin pairs, especially for factors with a strong genetic
component. Since lung function and CRP both are geneti-
cally determined, this could be a possible explanation.16,29
An alternative explanation could be that confounding
remains in the analysis of the entire cohort, despite
multivariate adjustment for major determinants of low lung
function. Although we find this explanation unlikely,
residual confounding can never be completely excluded.
This study was performed in a sample from the
population-based twin registry in Sweden. The lung func-
tion impairment was therefore mild in most cases, and only
five subjects were in stage 3 of the Global Initiative for
Chronic Obstructive Lung Disease (GOLD) classification.30
The relationships between lung function and biomarkers
could be different in a group of patients with clinically
significant COPD. The use of twins for the study could also
have influenced the outcome as the selection procedure
may have resulted in an over-representation of certain
groups, or because genetic factors may influence the rela-
tionships studied. However, we have not found any inherent
problems in the data that would invalidate the results.
Longitudinal studies are needed to address whether the
biomarkers are associated with a declining lung function
and disease progression.
In conclusion, several relationships with lung function
could be found among the blood markers in this panel of
proposed biomarkers for COPD. When subjects with COPD
were analyzed separately, CRP and desmosines showed
substantial correlations with several measures of lung
function. These biomarkers are assumed to reflect systemic
inflammation and elastin degradation.It is suggested that
CRP and desmosines could be useful markers of disease
severity in COPD.Conflicts of interest
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